将酒精使用与阿尔茨海默病联系起来:与衰老的相互作用和免疫路径上的APOE
1Center for Alcohol and Addiction Studies, Brown University, Providence, RI 02912, USA.
Medical research archives
|November 15, 2024
概括
酒精使用,APOE基因型和衰老相互作用促进阿尔茨海默病. 这篇评论探讨了微生物转移,衰老和神经炎症等免疫路径,突出了潜在的预防认知衰退策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- APOE基因型是阿尔茨海默病 (AD) 的主要遗传风险因素.
- 酒精消费是全球痴呆症的重要因素,但其机制尚未完全理解.
- 衰老与免疫衰老和"炎症"有关,这有助于像AD这样的与年龄有关的疾病.
研究的目的:
- 审查酒精如何与APOE基因型和衰老相互作用.
- 探索三个关键免疫路径在促进AD中的作用:微生物转位,衰老相关分泌表型 (SASP) 和神经炎症.
- 确定预防AD发病和进展的潜在目标.
主要方法:
- 文献综述侧重于酒精,APOE基因型,衰老和免疫路径之间的相互作用.
- 在AD的背景下对微生物转移,SASP和神经炎症进行现有研究的分析.
- 综合发现,提出AD促进机制.
主要成果:
- 饮酒会加剧与APOE ε4基因型和衰老相关的风险.
- 微生物转移,SASP和神经炎症都与AD病变产生有关,受到酒精和APOE的影响.
- 这些路径代表了生活方式,遗传学和AD发展中的衰老之间的相互作用的关键点.
结论:
- 酒精,APOE基因型和衰老之间的相互作用通过免疫路径显著影响AD风险.
- 了解这些机制可以为开发新的预防和干预策略提供信息.
- 对这些途径的进一步研究对于缓解AD和延迟认知衰退至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:26Aging
37
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
37
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:27CNS Depressants: Alcohol and Nicotine
174
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
174
01:19Psychoneuroimmunology: Diabetes and Cancer
24
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
24
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
41
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
41